Evaxion A/S (EVAX) Aktienanalyse

Unternehmensübersicht

Evaxion A/S operates as a clinical-stage biotechnology firm dedicated to the development of artificial intelligence-powered immunology vaccines designed to enhance the immune system's response against various pathologies. Within the broader Healthcare sector and the specific Biotechnology industry, the company focuses on leveraging advanced computational methods to create novel therapeutic interventions, positioning itself at the intersection of data science and biological research. The organization employs a workforce of 46 individuals and maintains a market capitalization of $33.86M while generating a Trailing Twelve Months revenue of $7.53M. These financial figures indicate that the company functions as a micro-cap entity with a relatively small operational footprint, which is typical for firms in the early clinical phases of drug development where significant capital is directed toward research and clinical trials rather than large-scale commercial production or distribution networks.

Finanzielle Gesundheit

The company reported a revenue of $7.53M over the trailing twelve months, yet recorded a net income of $-7,707,000, revealing a substantial gap where operating expenses significantly exceeded total income. This discrepancy highlights a cost structure heavily weighted toward research and development expenditures, which is characteristic of biotechnology firms investing heavily in Phase 2 clinical trials for their pipeline assets. The company generated an EBITDA of $-8,873,000 and reported a free cash flow of $-4,449,750, indicating that current operations are burning cash to fund its development programs rather than generating liquidity from sales. The balance sheet shows a cash reserve of $23.23M against total debt of $7.50M, suggesting that despite the negative cash flow, the firm currently holds a net cash position that provides a buffer for ongoing operations. Analyzing the profitability metrics, the gross margin stands at 100.0%, reflecting the nature of biotech revenue recognition before high development costs are allocated, while the operating margin is -122.7% and the profit margin is -102.4%, both indicating that the company is currently operating at a loss as it scales its clinical pipeline. The current ratio is listed at 5.85, which suggests a robust short-term liquidity position capable of covering short-term obligations multiple times over. Regarding return metrics, the Return on Equity is -100.2% and the Return on Assets is -28.2%, figures that mathematically reflect the company's current stage of investment where capital is being deployed to build value rather than generating immediate financial returns.

Bewertungsanalyse

The valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to negative earnings, contrasted by a forward P/E of 101.50 which implies that the market prices in expected future profitability despite current losses. The price-to-book ratio is 1.99, indicating that the market values the company at nearly twice its net asset value, a premium often seen in biotech firms where intangible assets like intellectual property and clinical trial data are not fully captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 4.50 and an EV/EBITDA of -189.04, the latter being negative because EBITDA is currently negative, which makes traditional earnings-based multiples less relevant for assessing intrinsic value at this stage. The stock's recent trading range is defined by a 52-week high of $12.15 and a 52-week low of $1.20, placing the current valuation within a wide band that reflects the high volatility associated with clinical-stage assets. The beta value is 0.20, which indicates that the stock's price volatility is significantly lower than the broader market index, suggesting that price movements are driven more by company-specific clinical data than by general market sentiment.

Growth & Income

The revenue growth year-over-year is -100.0%, while the earnings growth year-over-year is N/A due to the absence of prior period profitability or current earnings. This negative revenue growth figure indicates a contraction in sales, which may stem from the cessation of revenue from a previous product lifecycle or the transition period where revenue has not yet been recognized from new pipeline assets. Since the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that any potential earnings or cash reserves are retained entirely within the company to fund further research and development activities. This reinvestment strategy is standard for clinical-stage biotechnology companies that prioritize funding their pipeline and clinical trials over distributing capital to shareholders.